Effects of intravenous administration of pentoxifylline in pancreatic ischaemia–reperfusion injury  by Le Campion, Edmond Raymond et al.
ORIGINAL ARTICLE
Effects of intravenous administration of pentoxifylline in pancreatic
ischaemia–reperfusion injury
Edmond Raymond Le Campion, Jose Jukemura, Ana Maria Coelho, Rosely Patzina &
Luiz Augusto Carneiro D'Albuquerque
Division of Digestive Tract Transplantation (LIM/37), Department of Gastroenterology, University of São Paulo, São Paulo, Brazil
Abstract
Background: Therapeutic strategies to reduce the occurrence of pancreatic ischaemia–reperfusion (I–R)
injury might improve outcomes in human pancreas and kidney transplantation. In addition to its haem-
orrheologic effects, pentoxifylline has an anti-inflammatory effect by inhibiting NF-kB activation. This
group has previously demonstrated that pentoxifylline induces an anti-inflammatory response in acute
pancreatitis and liver I–R models. This led to the hypothesis that pentoxifylline might reduce pancreatic
and renal lesions and the systemic inflammatory response in pancreatic I–R injury. The aim of this
experimental study was to evaluate the effect of pentoxifylline administration in a rat model of pancreatic
I–R injury.
Methods: Pancreatic I–R was performed in Wistar rats over 1 h by clamping the splenic vessels. The
animals submitted to I–R were divided into two groups: Group 1 (n = 20, control) rats received saline
solution administered i.v. at 45 min after ischaemia, and Group 2 (n = 20) rats received pentoxifylline
(25 mg/kg) administered i.v. at 45 min after ischaemia. Blood samples were collected to enable the
determination of amylase, creatinine, tumour necrosis factor-a (TNF-a), interleukin-6 (IL-6) and IL-10.
Pancreatic malondialdehyde (MDA) content, pancreas histology and pulmonary myeloperoxidase (MPO)
were also assessed.
Results: Significant reductions in serum TNF-a, IL-6 and IL-10 were observed in Group 2 compared with
Group 1 (P < 0.05). No differences in pancreatic MDA content or serum amylase levels were observed
between the two groups. The histologic score was significantly lower in pentoxifylline-treated animals,
denoting less severe pancreatic histologic damage.
Conclusions: Pentoxifylline administration reduced the systemic inflammatory response, the pancreatic
histological lesion and renal dysfunction in pancreatic I–R injury and may be a useful tool in pancreas and
kidney transplantation.
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Introduction
Ischaemic–reperfusion (I–R) injury occurs relatively frequently in
numerous clinical interventions and physiopathological proc-
esses, especially in organ transplants.1 It is caused by an interrup-
tion of blood flow or ischaemia and consequent reperfusion, an
event that can cause disorders, both local and systemic, that affect
the recovery of patients after surgery.2
Pancreas transplantation has become the first treatment option
for patients with type 1 diabetes. Despite new protocols for immu-
nosuppression, improvements in organ preservation solution
and developments in surgical techniques, I–R syndrome remains
an important cause of tissue injury in organ transplant reci-
pients.3 Different experimental studies have tried to identify
mediators involved in the systemic inflammatory response, which
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is associated with alterations in microcirculation, such as increased
vascular permeability, arterial constriction, stasis of capillary
vessels and high levels of circulating pancreatic enzymes.4 These
alterations can lead to several complications such as acute pancrea-
titis, thrombosis, infection and graft loss.5
Graft pancreatitis as a result of I–R injury occurs in 17–35% of
patients undergoing pancreas transplantation and may contribute
to graft loss and kidney injury, thereby increasing morbidity in
these patients.6,7 It is believed that part of its pathogenesis is
related to microcirculatory disorders seen in pancreatic I–R
injury. The inhibition of inflammatory mediators involved in this
pathogenesis has been studied in some experimental models.8–11
Pentoxifylline is a methylxanthine derivative which acts as a
phosphodiesterase and NF-kB signal inhibitor with haemorrheo-
logic properties. It is able to increase blood cell deformability,
decrease platelet aggregation and lower blood viscosity, reducing
thrombus formation. It also exhibits marked anti-inflammatory
properties, mediated by inhibition of tumour necrosis factor-a
(TNF-a) production.12,13 A previous study conducted by the
present group demonstrated that pentoxifylline achieves an anti-
inflammatory response in acute pancreatitis.14
Therapeutic strategies to reduce pancreatic I–R injury might
improve outcomes in human pancreas and kidney transplanta-
tion, and thus pentoxifylline may be useful in reducing the inflam-
matory response and decreasing complications such as graft loss
in patients undergoing pancreas transplant. The aim of this
experimental study was to evaluate the effect of pentoxifylline
administration in a rat model of pancreatic I–R injury.
Materials and methods
Animals and surgical procedure
Sixty male Wistar rats, weighing 230–250 g, were housed in indi-
vidual cages under a controlled 12 : 12 h light–dark cycle, with
free access to standard chow and water ad libitum.
This study was designed in accordance with the Guidelines
for the Care and Use of Laboratory Animals (Medical Research
Laboratory – 37, Division of Digestive Tract Transplantation,
Department of Gastroenterology, University of Sao Paulo). The
experiment protocol was approved by the Ethics Committee of the
University of São Paulo, São Paulo, Brazil.
The animals were anaesthetized with intraperitoneal ketamine
(30 mg/kg) and xylazine (10 mg/kg), submitted to orotracheal
intubation, and ventilated with a tidal volume of 0.08 ml/g body
weight, at a respiratory rate of 60 breaths/min, and FiO2 of 0.21
(Small Animal Ventilator 683; Harvard Apparatus, Inc., Holliston,
MA, USA). During the surgical procedure, body temperature was
monitored using a rectal digital thermometer (Precision™ 4000A;
YSI, Inc., Yellow Springs, OH, USA) and was maintained at 37 °C.
Pancreatic I–R model
A pancreatic I–R model was established as described elsewhere.15
The upper abdomen was opened by a longitudinal laparotomy.
The stomach was turned up cranially using two stay sutures
(Nylon® 5–0). To minimize pancreatic injury, a no-touch tech-
nique was utilized, using the spleen as a grip. The pancreas was
carefully separated from the stomach and the short gastric vessels
were ligated. Some arterial arcades from the inferior pancreati-
coduodenal artery to the splenic artery were ligated. Thus, com-
plete vascular isolation of the pancreatic tail pedunculated on the
splenic vessels was achieved. For the induction of ischaemia in the
isolated pancreatic tail, one vascular microclamp was applied to
the splenic vessels. Ischaemia was induced for 1 h. After achieving
ischaemia, the microclamp was removed and pancreatic revascu-
larization was achieved followed by 4 h or 24 h of reperfusion. The
abdominal wall remained closed during the I–R period. Blood and
tissue samples (pancreas, kidney and lungs) were collected after
4 h h or 24 h of reperfusion.
Pentoxifylline and saline administration
Intravenous administration of pentoxifylline, at 25 mg/kg of
animal weight (1.25 ml/kg) (Trental™; Sanofi Aventis Pharma,
São Paulo, SP, Brazil), injected via the dorsal penial vein, was
performed 15 min before reperfusion and the same dose was
repeated after 12 h of reperfusion.
Intravenous administration of saline solution, at 1.25 ml/kg of
animal weight, injected via the dorsal penial vein, was performed
15 min before reperfusion and repeated after 12 h of reperfusion.
Experiment design
Animals were divided into three experiment groups: rats in the
sham group (n = 20) rats were subjected to laparotomy only
without manipulation of the pancreas; rats in Group 1 (n = 20)
were subjected to the pancreatic I–R procedure plus i.v. adminis-
tration of saline solution, and rats in Group 2 (n = 20) were
subjected to the pancreatic I–R procedure plus i.v. administration
of pentoxifylline.
Rats in Groups 1 and 2 were subjected to laparotomy and 1 h of
ischaemia, followed by either 4 h of reperfusion (n = 10 from each
group) or 24 h of reperfusion (n = 10 from each group).
Sample preparation
At 4 h and 24 h after reperfusion of the pancreas, animals were
re-anaesthetized for blood sampling through cardiac puncture and
killed by exsanguination. Serum samples were assayed for amylase
activity,16 inflammatory mediators [TNF-a, interleukin-6 (IL-6)
and IL-10], urea and creatinine. The pancreas tissue was obtained
from pancreatic tail portions previously submitted to I–R injury
and collected for evaluation of malondialdehyde (MDA) and his-
tological examination. Lung myeloperoxidase (MPO) activity was
analysed in lung homogenates 24 h after reperfusion.
Cytokine levels
Serum levels of TNF-a, IL-6 and IL-10 were determined by a
solid-phase sandwich enzyme-linked immunosorbent assay
(ELISA) using commercial kits (Invitrogen Corp., Camarillo, CA,
USA).
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MDA determination
Malondialdehyde levels in the pancreas samples were determined
to obtain a quantitative estimate of membrane lipid oxidative
damage. Malondialdehyde was assayed in terms of thiobarbituric
acid reactive substances. Pancreas tissues (100 mg/ml) were
homogenized in 1.15% KCl buffer and centrifuged at 14 000 g for
20 min. The supernatant was then stored at - 80 °C. An aliquot of
the supernatant was added to a reaction mixture of 1.5 ml 0.8%
thiobarbituric acid, 200 ml 8.1% (v/v) SDS, 1.5 ml 20% (v/v)
acetic acid, pH 3.5, and 300 ml distilled H2O and heated to 90 °C
for 45 min. After cooling to room temperature, the samples were
cleared by centrifugation at 10 000 g for 10 min, and their absorb-
ance was measured at 532 nm using malondialdehyde bis
(dimethyl acetal) as an external standard. The quantity of
lipid peroxides is reported in nanomole MDA equivalents/mg
protein.17
Lung myeoloperoxidase activity
Myeloperoxidase activity was used as an indicator of neutrophil
presence. Samples of lung tissue were homogenized with a
Polytron homogenizer using a homogenization buffer, which
contained 0.5% of hexadecyltrimethyl ammonium bromide,
5 mmol/l of EDTA, and 50 mmol/l of phosphate at pH 6.0.
Homogenized samples were then sonicated and centrifuged
(3 000 g, 30 min) at 4 °C. Myeloperoxidase activity in the super-
natant was assayed by measuring the change in absorption at
460 nm resulting from the metabolism of hydrogen peroxide
(H2O2) in the presence of O-dianisidine.18,19 Results are expressed
as optical density at 460 nm.
Histological analysis
Pancreatic tissue samples were fixed in 10% formaldehyde solu-
tion, embedded in paraffin, sectioned, and stained with haema-
toxylin and eosin for light microscopy. Histological analysis was
performed by the same pathologist in a blinded manner. The
severity of necrotizing pancreatitis was determined according to a
previously described scoring system (Table 1).20 This score
includes the graded assessment of pancreatic oedema, inflamma-
tory infiltration, pancreatic necrosis, pancreatic haemorrhage, and
extrapancreatic fat necrosis. A scale of 0–4 was used.
Statistical analysis
Results are reported as the mean and standard error of the mean
(SEM). Continuous variables (amylase activity, creatinine, urea,
TNF-a, IL-6, IL-10, MDA and MPO activity) were analysed using
analysis of variance (anova). Histological analysis was deter-
mined using the Kruskal–Wallis test. A P-value of < 0.05 was
considered to indicate statistical significance. Statistical analyses
were conducted using GraphPad Prism Version 2011 for Mac
(GraphPad Software, Inc., San Diego, CA, USA).
Results
Cytokine levels
Serum levels of TNF-a, IL-6 and IL-10 were undetectable in the
sham group. High levels of cytokines were observed in Group 1
(I–R without treatment). By contrast, significant decreases in
TNF-a (P = 0.0002), IL-6 (P = 0.031) and IL-10 (P = 0.011) were
observed 4 h after reperfusion in Group 2 compared with Group 1
(Fig. 1a–c). A marked reduction in the TNF-a : IL-10 ratio was
observed in Group 2, showing a greater degree of anti-
inflammatory activity in this group compared with Group 1
(P = 0.001) (Fig. 2).
Serum levels of amylase, creatinine and urea
Serum amylase levels were 5.97  0.70 mg/ml/min, 8.56 
2.21 mg/ml/min and 8.91  1.62 mg/ml/min in the sham group
and Groups 1 and 2, respectively. There was a significant increase
in serum amylase levels in the pancreatic I–R groups (Groups 1
Table 1 Histological scoring criteria
Oedema
0 Absent
0.5 Focal expansion of interlobar septae
1.0 Diffuse expansion of interlobar septae
1.5 As 1.0, with focal expansion of interlobular septae
2.0 As 1.0, with diffuse expansion of interlobular septae
2.5 As 2.0, with focal expansion of interacinar septae
3.0 As 2.0, with diffuse expansion of interacinar septae
3.5 As 3.0, with focal expansion of intercellular spaces
4.0 As 3.0, with diffuse expansion of intercellular spaces
Acinar necrosis
0 Absent
0.5 Focal occurrence of 1–4 necrotic cells/HPF
1.0 Diffuse occurrence of 1–4 necrotic cells/HPF
1.5 As 1.0, with focal occurrence of 5–10 necrotic cells/HPF
2.0 Diffuse occurrence of 5–10 necrotic cells/HPF
2.5 As 2.0, with focal occurrence of 11–16 necrotic cells/HPF
3.0 Diffuse occurrence of 1–16 necrotic cells/HPF (foci of confluent
necrosis)
3.5 As 3.0, with focal occurrence of > 16 necrotic cells/HPF
4.0 > 16 necrotic cells/HPF (extensive confluent necrosis)
Haemorrhage and fat necrosis
0 Absent
0.5 1 focus
1.0 2 foci
1.5 3 foci
2.0 4 foci
2.5 5 foci
3.0 6 foci
3.5 7 foci
4.0  8 foci
Inflammation and perivascular infiltrate
0 0–1 intralobular or perivascular leukocytes/HPF
0.5 2–5 intralobular or perivascular leukocytes/HPF
1.0 6–10 intralobular or perivascular leukocytes/HPF
1.5 11–15 intralobular or perivascular leukocytes/HPF
2.0 16–20 intralobular or perivascular leukocytes/HPF
2.5 21–25 intralobular or perivascular leukocytes/HPF
3.0 26–30 intralobular or perivascular leukocytes/HPF
3.5 > 30 leukocytes/HPF or focal microabscesses
4.0 > 35 leukocytes/HPF or confluent microabscesses
HPF, high-power field.
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and 2) compared with the sham group (P < 0.05), but the differ-
ence between serum amylase levels in Groups 1 and 2 did not
reach statistical significance (P = 0.692).
Serum creatinine levels were 0.39  0.06 mg/dl, 0.68 
0.39 mg/dl and 0.43 0.13 mg/dl in the sham group, and Groups
1 and 2, respectively. A significant increase in serum creatinine
levels was observed in Group 1 compared with the sham group
(P < 0.05). There was no statistical difference between Groups 1
and 2. However, the results show a trend towards a reduction in
renal dysfunction in Group 2 (P = 0.070).
No difference in urea levels was observed among the groups
(P = 0.794).
Determination of MDA
The administration of pentoxifylline did not significantly affect
pancreatic content of MDA in animals with I–R injury.
Lung MPO activity
To assess lung inflammation by neutrophil infiltration, MPO
activity was measured. Results at 24 h at 460 nm were 0.04 0.02,
0.08 0.03 and 0.06 0.02 in the sham group, and Groups 1 and
2, respectively. There was a significant increase in lung MPO activ-
ity in rats submitted to I–R (Groups 1 and 2) compared with the
sham group (P < 0.05). However, there was no significant differ-
ence in MPO activity between Groups 1 and 2 (P = 0.293).
Histological analysis
Histological scores at 24 h in Group 2 were significantly lower
than in Group 1, denoting less severe pancreatic histological
damage (Table 2) (Fig. 3).
Discussion
Pentoxifylline is a methylxanthine phosphodiesterase inhibitor
that is used to treat chronic vascular diseases. It has interesting
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pharmacological properties in that it is able to decrease platelet
aggregation, increase red cell deformability and lower blood vis-
cosity.21,22 In addition, it attenuates the release of proinflammatory
cytokines and blocks the production of TNF-a by inhibiting
intracellular phosphodiesterase.12,13 These properties seem to
reduce local and systemic inflammation, causing less I–R injury.
A variety of studies have shown a protective effect of some
pharmacological substances, such as L-arginine, octreotide, NAC
and others, in I–R injury.7,23–27 Aslan et al.28 and Kaptanoglu et al.29
have demonstrated that the use of pentoxifylline reduces I–R
injury in the liver and contributes to hepatic cytoprotection by
increasing and decreasing, respectively, liver tissue levels of pros-
taglandin E2 and serum levels of alanine transaminase (ALT) and
aspartate transaminase (AST). Recently, pentoxifylline has been
shown to be able to attenuate local and systemic inflammatory
responses, as well as reduce pancreatic infection and mortality
rates in experimental acute pancreatitis.14,30
The systemic inflammatory response is mediated by cytokines
and there is evidence that serum levels of TNF-a, IL-1 and IL-6 are
increased early in the course of acute pancreatitis and are corre-
lated with the severity of disease.31 In the present study, treatment
with pentoxifylline reduced the systemic inflammatory response
in pancreatic I–R injury. Indeed, significant decreases in serum
levels of TNF-a and IL-6 were observed in Group 2 compared
with Group 1 (Fig. 1). By contrast, an analysis of the relationship
of inflammatory cytokines with anti-inflammatory cytokines
(ratio of TNF-a : IL-10) showed a higher anti-inflammatory
response in Group 2. Further studies also showed that treatment
with pentoxifylline in hepatic I–R caused a significant decrease
in serum TNF-a as a result of the inhibition of TNF mRNA
expression.32
The present experimental model caused acute pancreatitis sec-
ondary to ischaemia,a condition that occurs in pancreas transplan-
tation. Indeed, high serum levels of amylase were evident in Groups
1 and 2. The i.v. administration of pentoxifylline did not reduce
serum levels of amylase in comparison with the control group,
suggesting that this drug does not prevent acute pancreatitis. The
same result was seen in another study in which NAC was adminis-
tered i.v. during pancreatic I–R induction.23
In this study, pancreatic I–R promoted renal dysfunction, which
proved to be caused by higher serum levels of creatinine in Group
1 compared with the sham group. This effect may be attributable
to the increased inflammatory response caused by I–R injury.
Because pentoxifylline reduces levels of inflammatory cytokines, it
may improve renal function when administered before pancreatic
reperfusion. According to the present experiment, an improve-
ment in renal function occurred with the administration of pen-
toxifylline, but this result was not statistically significant (P =
0.07). A recent study demonstrated that pentoxifylline did not
protect renal function in a model of unilateral hind limb I–R
injury, but probably impaired it.33
Ischaemia–reperfusion injury is known to lead to the activa-
tion of neutrophils and to generate reactive oxygen species
(ROS), causing oxidative stress and consequential organ dysfunc-
tion.34 The lipid peroxidation is involved in this process, produc-
ing some metabolites such as MDA. Data reported in the
literature on the effect of pentoxifylline against oxidative stress
are contradictory. Sener et al.35 demonstrated that pentoxifylline
was able to significantly reduce lipid peroxidation in an intestinal
I–R injury model, evidenced by diminished ileal MDA levels.
However, in the present study, its use failed to reduce oxidative
stress significantly compared with Group 1 (results not signifi-
cant). Similarly, other authors have shown that pentoxifylline was
unable to reduce serum lipid hydroperoxide levels in a laparo-
scopic I–R model.36
At 24 h after pancreas reperfusion, MPO activity was observed
in lung homogenates, indicating that pancreatic I–R induced neu-
trophil infiltration and, consequently, lung injury. However, treat-
ment with pentoxifylline did not decrease lung MPO activity in
the present experiment. Thus, TNF-a blockage by pentoxifylline
did not prevent lung inflammation, probably because TNF-a is
not the only cytokine responsible for the development of neu-
trophil infiltration or because its suppression does not affect other
activation pathways of the systemic inflammatory response. In a
previous study, the present group has also shown that experimen-
tal acute pancreatitis causes lung inflammation, and pretreatment
Table 2 Pancreatic histological grading lesion at 24 h after
ischaemia–reperfusion injury
Group 1 Group 2 Sham group
Median  SD 6.05  2.68 3.55  0.86a 1.75  0.82
95% CI 4.13–7.97 2.93–4.17 1.16–2.34
Sum of median values (oedema, acinar necrosis, haemorrhage and fat
necrosis, inflammation and perivascular infiltrate)  standard error of the
mean.
aP < 0.05 for Group 2 versus Group 1.
SD, standard deviation; 95% CI, 95% confidence interval.
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with carbon dioxide (CO2) abdominal insufflation attenuated the
systemic inflammatory response but did not alter lung MPO
activity.37 By contrast, Kim et al.38 have shown that valproic acid
decreases neutrophil migration into the lungs after intestinal I–R
injury in rats.
In support of the findings of the beneficial effects of pentoxi-
fylline on the systemic inflammatory response, histological analy-
sis was more favourable in Group 2 than in Group 1 (Table 2 and
Fig. 3), denoting less pancreatic tissue damage. Indeed, other
studies have shown that this drug reduces local tissue damage in
some organs after I–R injury.31,39
In conclusion, the administration of pentoxifylline was found
to improve the inflammatory response, reduce serum cytokine
levels and decrease pancreatic tissue damage in this experimental
model of I–R injury, a condition that can occur in simultaneous
pancreas and kidney transplant procedures. Further clinical trials
are necessary to confirm the benefits of pentoxifylline in the trans-
plant setting.
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